1. Academic Validation
  2. Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5)

Synthesis and initial evaluation of novel, non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5)

  • Bioorg Med Chem Lett. 2009 Jan 15;19(2):352-5. doi: 10.1016/j.bmcl.2008.11.074.
Jeffrey J Letourneau 1 Jinqi Liu Michael H J Ohlmeyer Chris Riviello Yajing Rong Hong Li Kenneth C Appell Shalini Bansal Biji Jacob Angela Wong Maria L Webb
Affiliations

Affiliation

  • 1 Department of Chemistry, Pharmacopeia, Inc., PO Box 5350, Princeton, NJ 08543, USA. jletourn@pcop.com
Abstract

The discovery, synthesis and preliminary SAR of a novel class of non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5) is described. High-throughput screening of an extensive series of ECLiPStrade MARK compound libraries led to the identification of compound 1 as a dual inhibitor of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). Optimization of compound 1 involving, in part, introduction of two novel constraints led to the discovery of compounds 15a and 15b with reduced PSA and much improved potency for both the alpha(v)beta(3) and alpha(v)beta(5) integrins. Compounds 15a and 15b were shown to have promising activity in functional cellular assays and compound 15a also exhibited a promising Caco-2 permeability profile.

Figures